In the first trial of microRNA inhibition to treat heart failure, a novel agent did not reduce left ventricular end-systolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results